Anti-TPP1 Polyclonal Antibody

Catalog No.

PHA29601

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human TPP1 (Met1-Val320).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Cell growth-inhibiting gene 1 protein, LPIC, Tripeptidyl-peptidase 1, Tripeptidyl aminopeptidase, Lysosomal pepstatin-insensitive protease, TPP1, CLN2, TPP-I, TPP-1, Tripeptidyl-peptidase I

Purification

Purified by antigen affinity column.

Accession

O14773

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC., PMID:35612299

Autocrine GMCSF Signaling Contributes to Growth of HER2+ Breast Leptomeningeal Carcinomatosis., PMID:34247146

The intrinsically disordered N-terminal region of mouse DNA polymerase alpha mediates its interaction with POT1a/b at telomeres., PMID:33711210

Identification of tumor-associated antigens of lung cancer: SEREX combined with bioinformatics analysis., PMID:33587914

Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration., PMID:33202105

Mechanisms Inspired Targeting Peptides., PMID:32185724

Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study., PMID:30205177

Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy., PMID:29217732

Telomere Dysfunction Induced Foci (TIF) Analysis., PMID:27500188

Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis., PMID:25257657

Telomerase enzymatic component hTERT shortens long telomeres in human cells., PMID:24721976

Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis., PMID:23131032

Altered expression of TPP1 in fibroblast-like synovial cells might be involved in the pathogenesis of rheumatoid arthritis., PMID:21833529

Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis., PMID:21784683

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA., PMID:18473686

Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency., PMID:18283468

Two novel CLN5 mutations in a Portuguese patient with vLINCL: insights into molecular mechanisms of CLN5 deficiency., PMID:16814585

Overexpression in colorectal carcinoma of two lysosomal enzymes, CLN2 and CLN1, involved in neuronal ceroid lipofuscinosis., PMID:16518810

Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders., PMID:11589013

Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase., PMID:10965052

Rapid immunologic diagnosis of classic late infantile neuronal ceroid lipofuscinosis., PMID:10762513

A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase., PMID:10349869

The expression of late infantile neuronal ceroid lipofuscinosis (CLN2) gene product in human brains., PMID:9865940

Document Download

Anti-TPP1 Polyclonal Antibody.pdf